Capital Wealth Planning LLC Purchases 8,746 Shares of Cencora, Inc. $COR

Capital Wealth Planning LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 156.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,351 shares of the company’s stock after buying an additional 8,746 shares during the quarter. Capital Wealth Planning LLC’s holdings in Cencora were worth $4,485,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. United Bank lifted its stake in Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after acquiring an additional 305 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Cencora by 10.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 27,773 shares of the company’s stock worth $8,328,000 after acquiring an additional 2,613 shares in the last quarter. Impax Asset Management Group plc raised its holdings in shares of Cencora by 68.3% in the second quarter. Impax Asset Management Group plc now owns 4,008 shares of the company’s stock valued at $1,202,000 after purchasing an additional 1,627 shares during the last quarter. Candriam S.C.A. raised its holdings in shares of Cencora by 326.7% in the second quarter. Candriam S.C.A. now owns 31,095 shares of the company’s stock valued at $9,324,000 after purchasing an additional 23,808 shares during the last quarter. Finally, D Orazio & Associates Inc. bought a new stake in shares of Cencora in the second quarter worth $218,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Evercore decreased their target price on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Robert W. Baird set a $415.00 price objective on Cencora in a report on Tuesday, January 13th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 15,220 shares of company stock valued at $5,282,867. Company insiders own 0.38% of the company’s stock.

Cencora Stock Down 0.8%

COR opened at $349.69 on Friday. Cencora, Inc. has a 1-year low of $252.49 and a 1-year high of $377.54. The stock’s fifty day simple moving average is $355.58 and its 200 day simple moving average is $338.13. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The stock has a market cap of $68.03 billion, a PE ratio of 42.03, a price-to-earnings-growth ratio of 1.64 and a beta of 0.68.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period in the previous year, the business posted $3.73 earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is presently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.